# US 2016/0256579 A1 · Method for labeling a prostate-specific membrane antigen ligand with a radioactive isotope

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256579 A1
- Document ID: US20160256579A1
- Status: Published application
- Kind: A1
- Application number: 15/058,537
- Filed: 2016-03-02
- Published: 2016-09-08
- Earliest claimed: 2015-03-03
- Assignees: Isotopia Molecular Imaging Ltd.
- Applicants: Isotopia Molecular Imaging Ltd.
- Inventors: Eli Shalom
- Web page: https://patentgrep.com/patent/US20160256579A1

## CPC

- A61K 51/0472: {containing heavy metals, e.g. hemin, hematin, melarsoprol}
- A61K 51/0402: {carboxylic acid carriers, fatty acids (amino acids A61K51/0406)}
- A61K 51/0478: {complexes from non-cyclic ligands, e.g. EDTA, MAG3}
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- C07B 59/004: {Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium}
- C07F 5/00: Compounds containing elements of Groups 3 or 13 of the Periodic Table
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

A method for labeling a prostate-specific membrane antigen (PSMA) ligand with a radioactive isotope, such as 68Ga, 177Lu, or 90Y, includes providing a reaction vial containing a sodium-based buffering agent and the PSMA ligand, both in dried form; adding a solution of the radioactive isotope in HCl to the reaction vial, thus obtaining a solution of the PSMA ligand and the radioactive isotope in the HCl; and mixing the solution and then incubating it for a sufficient period of time, thus reacting the PSMA ligand with the radioactive isotope to thereby obtain the PSMA ligand labeled with the radioactive isotope, At least 90% of the radioactive isotope in the solution is bound to the PSMA ligand. A kit can be used for carrying out the method. Radiolabeled PSMA ligands prepared by this method can be used for both imaging and therapy.

## Claims

### Claim 1

A method for labeling a prostate-specific membrane antigen (PSMA) ligand with a radioactive isotope selected from the group consisting of 68Ga, 177Lu, and 90Y, comprising:
(i) providing a reaction vial containing a predetermined amounts of a sodium-based buffering agent and said PSMA ligand, both in dried form;
(ii) adding a solution of said radioactive isotope in a predetermined amount of HCl having a predetermined molarity to said reaction vial, thus obtaining a solution of said PSMA ligand and said radioactive isotope in said HCl;
(iii) mixing the solution obtained in (ii) and then incubating it for a sufficient period of time, thus reacting said PSMA ligand with said radioactive isotope to thereby obtain said PSMA ligand labeled with said radioactive isotope, wherein at least 90% of said radioactive isotope in said solution is bound to said PSMA ligand; and
(iv) optionally adjusting the pH of the solution in said reaction vial to a pH compatible with physiological conditions by adding a sodium-based buffering agent,
wherein said PSMA ligand is represented by a general formula I:
R1—CO—R2-L-B—X (I)
wherein
B is a chelating agent capable of coordinating with said radioactive isotope;
X is absent or is of the formula -L′-R2′—CO—R1;
L and L′ each independently is absent or a linker;
R1 and R1′ each independently is an amino acid residue linked via an amino group thereof to the adjacent —CO— group; and
R2 and R2′ each independently is an amino acid residue linked via an amino group thereof to the adjacent —CO— group.

### Claim 2 (depends on 1)

The method of claim 1, wherein R1 and R1′, if present, are a glutamic acid residue.

### Claim 3 (depends on 1)

The method of claim 1, wherein R2 and R2′, if present, are a glutamic acid residue or a lysine residue.

### Claim 4 (depends on 1)

The method of claim 1, wherein L and L′ each independently is absent or the linker selected from the group consisting of an amino acid residue forming a peptide bond with R2 or R2′, respectively, a peptide moiety consisting of 2-6 amino acid residues and forming a peptide bond with R2 or R2′, respectively, (C1-C8)alkylene, (C2-C8)alkenylene and (C2-C8)alkynylene, wherein said (C1-C8)alkylene, (C2-C8)alkenylene and (C2-C8)alkynylene is optionally substituted with one or more groups each independently is selected from the group consisting of halogen, —COR3, —COOR3, —OCOOR3, —OCON(R3)2, —CN, —NO2, —SR3, —OR3, —N(R3)2, —CON(R3)2, —SO2R3, —SO3H, and —S(═O)R3, and further optionally interrupted by one or more identical or different heteroatoms selected from the group consisting of S, O and N, and/or at least one group selected from the group consisting of —NH—CO—, —CO—NH—, and —N(C1-C8alkyl)-, wherein R3 each independently is selected from the group consisting of hydrogen, and —(C1-C8)alkyl.

### Claim 5 (depends on 4)

The method of claim 4, wherein (i) said linker is an amino acid residue, or a peptide moiety consisting of 2-6 amino acid residues, wherein said amino acid each independently is 6-aminohexanoic acid, 8-aminooctanoic acid, 1-naphthylalanine (1Nal), 2-naphthylalanine (2Nal), or 4-(aminomethyl)cyclohexane carboxylic acid (Amc); or (ii) said linker each independently is (C1-C8)alkylene, (C2-C8)alkenylene or (C2-C8)alkynylene, optionally substituted with one or more groups each independently selected from the group consisting of halogen, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO2H, —SO3H, and —S(═O)H, and further optionally interrupted by one or more identical or different heteroatoms selected from the group consisting of S, O and N, and/or at least one group selected from the group consisting of —NH—CO—, —CO—NH—, and —N(C1-C8alkyl)-.

### Claim 6 (depends on 5)

The method of claim 5, wherein said linker is a residue of 6-aminohexanoic acid or 8-aminooctanoic acid, or a moiety of 1Nal-Amc, 2Nal-Amc, Amc-1Nal or Amc-2Nal.

### Claim 7 (depends on 1)

The method of claim 1, wherein said chelating agent is N,N′-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N′-diacetic acid (HBED-CC) or 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), forming amide bond with either L, if present, or R2, and when X is present, forming another amide bond with either L′, if present, or R2′.

### Claim 8 (depends on 1)

The method of claim 1, wherein:
R1 and R1′, if present, are a glutamic acid residue;
R2 and R2′, if present, are a glutamic acid residue or a lysine residue;
L and L′ each independently is absent or the linker selected from the group consisting of an amino acid residue forming a peptide bond with R2 or R2′, respectively, a peptide moiety consisting of 2-6 amino acid residues and forming a peptide bond with R2 or R2′, respectively, (C1-C8)alkylene, (C2-C8)alkenylene and (C2-C8)alkynylene, wherein said (C1-C8)alkylene, (C2-C8)alkenylene and (C2-C8)alkynylene each independently is optionally substituted with one or more groups each independently selected from the group consisting of halogen, —COR3, —COOR3, —OCOOR3, —OCON(R3)2, —CN, —NO2, —SR3, —OR3, —N(R3)2, —CON(R3)2, —SO2R3, —SO3H, and —S(═O)R3, and further optionally interrupted by one or more identical or different heteroatoms selected from the group consisting of S, O and N, and/or at least one group selected from the group consisting of —NH—CO—, —CO—NH—, and —N(C1-C8alkyl)-, wherein R3 each independently is selected from the group consisting of hydrogen, and —(C1-C8)alkyl; and
said chelating agent is HBED-CC or DOTA, forming an amide bond with either L, if present, or R2, and when X is present, forming another amide bond with either L′, if present, or R2′.

### Claim 9 (depends on 8)

The method of claim 8, wherein L and L′, if present, each independently is the linker selected from the group consisting of an amino acid residue, a peptide moiety consisting of 2-6 amino acid residues, (C1-C8)alkylene, (C2-C8)alkenylene and (C2-C8)alkynylene, wherein said amino acid each independently is 6-aminohexanoic acid, 8-aminooctanoic acid, 1Nal, 2Nal, or Amc; and said (C1-C8)alkylene, (C2-C8)alkenylene and (C2-C8)alkynylene is optionally substituted with one or more groups each independently selected from the group consisting of halogen, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO2H, —SO3H, and —S(═O)H, and further optionally interrupted by one or more identical or different heteroatoms selected from the group consisting of S, O and N, and/or at least one group selected from the group consisting of —NH—CO—, —CO—NH—, and —N(C1-C8alkyl)-.

### Claim 10 (depends on 9)

The method of claim 9, wherein L and L′ each independently is a residue of 6-aminohexanoic acid or 8-aminooctanoic acid, or a moiety of 1Nal-Amc, 2Nal-Amc, Amc-1Nal or Amc-2Nal.

### Claim 11 (depends on 10)

The method of claim 10, wherein (i) X is absent; R2 is a lysine residue linked via its α-amino group to the adjacent —CO— group; and (a) L is 6-aminohexanoic acid; and B is HBED-CC linked via a carboxylic group thereof to the amino group of the 6-aminohexanoic acid; or (b) L is Amc-2Nal or Amc-1Nal linked via the carboxylic group of the 2Nal or 1Nal, respectively, to the side chain amino group of R2; and B is DOTA linked via a carboxylic group thereof to the amino group of the Amc; or (ii) X is present; R2 and R2′ each is a lysine residue linked via its α-amino group to the adjacent —CO— group; L and L′ each is 6-aminohexanoic acid; and B is HBED-CC linked via one carboxylic group thereof to the amino group of L and via another carboxylic group thereof to the amino group of L′.

### Claim 12 (depends on 11)

The method of claim 11, wherein said radioactive isotope is 68Ga.

### Claim 13 (depends on 1)

The method of claim 1, wherein
(a) said reaction vial provided in (i) is pretreated with HCl; or
(b) said buffering agent in (i) is sodium formate, sodium ascorbate, sodium acetate, sodium hydroxide, or sodium citrate; or
(c) the solution added in (ii) to said reaction vial is obtained by eluting said radioactive isotope from a radioactive isotope generator, immediately before (ii), using said predetermined amount of HCl as an elution solvent; or
(d) said mixing in (iii) is carried out by stirring or shaking; or
(e) said radioactive isotope is 68Ga, and the solution in (iii) is incubated for 2 to 10 minutes at room temperature; or said radioactive isotope is 177Lu or 90Y, and the solution in (iii) is incubated for about 30 minutes or more at a temperature of about 100° C. or higher; or
(f) the pH of the solution in (iv) is adjusted to a pH in a range of 4.0 to 8.0, by adding sodium formate, sodium ascorbate, sodium acetate, sodium hydroxide, or sodium citrate.

### Claim 14

A method for labeling a PSMA ligand with 68Ga, comprising:
(i) providing a reaction vial containing about 800-1800 mg sodium formate and about 10 μg of said PSMA ligand, wherein both the sodium formate and said PSMA ligand are dried;
(ii) adding a solution of 68Ga in about 1.8 ml of HCl 0.1N to said reaction vial, thus obtaining a solution of said PSMA ligand and said 68Ga in said HCl, wherein said solution of 68Ga in HCl is obtained from a 68Ga generator, immediately before adding to said reaction vial, using said HCl as an elution solvent;
(iii) mixing the solution obtained in (ii) and then incubating it for 2 to 10 minutes at room temperature, thus reacting said PSMA ligand with said 68Ga and obtaining said PSMA ligand labeled with 68Ga; and
(iv) optionally adjusting the pH of the solution in said reaction vial to a pH in a range of 4.0 to 8.0, by adding about 0.1 ml sodium hydroxide 1N,
wherein said PSMA ligand is of the general formula I′:
R1—CO—R2-L-B (I′)
wherein
R1 is a glutamic acid residue linked via its amino group to the adjacent —CO— group; R2 is a lysine residue linked via its α-amino group to the adjacent —CO— group; and either: (a) L is 6-aminohexanoic acid linked via the carboxylic group thereof to the side chain amino group of R2; and B is HBED-CC linked via a carboxylic group thereof to the amino group of the 6-aminohexanoic acid; or (b) L is Amc-2Nal or Amc-1Nal linked via the carboxylic group of the 2Nal or 1Nal, respectively, to the side chain amino group of R2; and B is DOTA linked via a carboxylic group thereof to the amino group of the Amc.

### Claim 15

A method for labeling a PSMA ligand with 177Lu or 90Y,comprising:
(i) providing a reaction vial containing sodium formate and 10 μg of said PSMA ligand, wherein both the sodium formate and said PSMA ligand are dried;
(ii) adding a solution of 177Lu or 90Y in about 0.5 ml of HCl 0.1N to said reaction vial, thus obtaining a solution of said PSMA ligand and said 177Lu or 90Y in said HCl; and
(iii) mixing the solution obtained in (ii) and then incubating it for about 30 minutes at a temperature of about 100° C. or higher, thus reacting said PSMA ligand with said 177Lu or 90Y and obtaining said PSMA ligand labeled with 177Lu or 90Y,
wherein said PSMA ligand is represented by a general formula I′:
R1—CO—R2-L-B (I′)
wherein
R1 is a glutamic acid residue linked via its amino group to the adjacent —CO— group; R2 is a lysine residue linked via its α-amino group to the adjacent —CO— group; and L is Amc-2Nal or Amc-1Nal linked via the carboxylic group of the 2Nal or 1Nal, respectively, to the side chain amino group of R2; and B is DOTA linked via a carboxylic group thereof to the amino group of the Amc.

### Claim 16 (depends on 1)

In a method for imaging of prostate cancer or metastases thereof, the improvement comprising using as a PSMA ligand a PSMA ligand labeled with 68Ga by the method of claim 1.

### Claim 17 (depends on 1)

In a method for treating prostate cancer or metastases thereof, the improvement comprising using as a PSMA ligand a PSMA ligand labeled with 177Lu or 90Y by the method of claim 1.

### Claim 18 (depends on 1)

A kit comprising:
(i) a disposable reaction vial containing a predetermined amounts of both a sodium-based buffering agent and a PSMA ligand as defined in claim 1, both in dried form; or two disposable reaction vials, wherein one of said disposable reaction vials contains said sodium-based buffering agent and the other of said disposable reaction vials contains said PSMA ligand, both in dried form; and
(ii) instructions for optionally adding said sodium-based buffering agent to the reaction vial containing said PSMA ligand, and for labeling said PSMA ligand with a radioactive isotope.

### Claim 19 (depends on 18)

The kit of claim 18, wherein (i) said disposable reaction vial containing said PSMA ligand and optionally said sodium-based buffering agent is pretreated with HCl; or (ii) said sodium-based buffering agent is sodium formate, sodium ascorbate, sodium acetate, sodium hydroxide, or sodium citrate.

### Claim 20 (depends on 19)

The kit of claim 19, further comprising at least one of:
(i) a vial containing a predetermined amount of HCl having a molarity in a range of 0.05 to 0.1N for eluting said radioactive isotope from a radioactive isotope generator; and
(ii) a vial containing a sodium-based buffering agent for pH adjustment.
